N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Strides acquires the only FDA-approved integrated soft gel capsule manufacturing facility in the US, owned by Micelle, to support its operations in India.
Enteris enters a licensing agreement with Cara Therapeutics for the ongoing development of the latter’s drug candidate as it continues clinical trials.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
Genentech enters a manufacturing and development agreement with Enable Injections to advance the latter’s patient-administered subcutaneous drug delivery system.
